Physician profile
Glenn Kolansky
NPI 1740351683
$7,035.42
in general payments reported to CMS, 2019-2025
35 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $111 · 2021: $967 · 2022: $533 · 2023: $1,135 · 2024: $2,045 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,557 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,556.61 |
| Education | $261.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $942.33 | 2021-2025 | Tremfya, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $818.50 | 2023-2025 | Zoryve |
| Biofrontera INC. | $628.40 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $527.16 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $525.50 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $384.11 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $304.79 | 2022-2025 | Winlevi |
| Genzyme Corporation | $286.09 | 2021-2025 | |
| Almirall LLC | $240.38 | 2021-2025 | Klisyri, Seysara |
| Abbvie INC. | $225.10 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $202.52 | 2022-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $168.72 | 2021-2025 | |
| Incyte Corporation | $167.54 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $165.02 | 2024 | Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $140.08 | 2019-2022 | |
| Epi Health, LLC | $136.56 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $111.47 | 2021 | |
| Amgen INC. | $101.32 | 2023-2025 | Otezla |
| Sebela Pharmaceuticals INC. | $87.98 | 2019-2023 | Naftin |
| Allergan, INC. | $81.29 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $80.38 | 2021-2023 | |
| Organon LLC | $68.53 | 2025 | Vtama |
| Genentech USA, INC. | $42.51 | 2019-2022 | |
| Botanix Sb INC | $42.49 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $30.00 | 2024 | Daxxify |
| Lilly USA, LLC | $29.47 | 2022-2023 | Taltz, Olumiant |
| Nabriva Therapeutics, Plc | $27.28 | 2022 | |
| Merck Sharp & Dohme LLC | $25.62 | 2019 | |
| Kerecis Limited | $20.37 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Regeneron Healthcare Solutions, INC. | $17.70 | 2025 | Libtayo |
| Vifor Pharma, INC. | $16.37 | 2023 | Veltassa |
| Ucb, INC. | $14.93 | 2019 | |
| Kyowa Kirin, INC. | $12.78 | 2021 | |
| Pfizer INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Kolansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.